Table 2.
Variables | Intervention Group | Intervention Group Paired t test (P) | Control Group | Control Group Paired t test(P) | Baseline ANOVA analysis (P) | ANCOV Aanalysis(P) | ||
---|---|---|---|---|---|---|---|---|
(n = 26) | (n = 24) | |||||||
Baseline | 12 weeks | Baseline | 12 weeks | |||||
SF-36 | ||||||||
PF | 82.12(10.69) | 86.73(7.87) | 0.085 | 78.96(18.88) | 85.21(10.78) | 0.079 | 0.466 | 0.735 |
RP | 32.69(38.58) | 57.69(37.93) | O.009* | 59.38(42.23) | 53.13(41.25) | 0.519 | 0.057 | 0.142 |
BP | 73.46(13.84) | 77.31(13.43) | 0,290 | 73.33(18.10) | 79.58(16.28) | 0.189 | 0.978 | 0.590 |
GH | 65.96(15.85) | 73.38(18.16) | 0.024* | 57.21(19.80) | 63.08(18.90) | 0.054 | 0.090 | 0.300 |
VT | 61.92(11.67) | 67.12(5.86) | 0.014* | 62.71(8.84) | 62.08(10.31) | 0.700 | 0.791 | 0.009* |
SF | 88.94(17.08) | 95.67(17.30) | 0.148 | 85.42(24.91) | 93.75(21.49) | 0.103 | 0.560 | 0.872 |
RE | 61.54(40.76) | 74.36(33.08) | 0.144 | 56.94(44.48) | 69.44(40.43) | 0.131 | 0.705 | 0.744 |
MH | 51.08(6.23) | 54.62(4.92) | 0.014* | 51.83(6.62) | 49.83(5.53) | 0.197 | 0.679 | 0.001* |
HT | 2.42(1.14) | 1.65(0.94) | 0.007* | 2.46(1.28) | 2.17(0.82) | 0.373 | 0.918 | 0.048* |
SPSDCT | 14.81(2.93) | 19.31(4.32) | 0.000* | 15.17(3.41) | 15.67(3.69) | 0.180 | 0.691 | 0.000* |
ALT | 16.08(5.01) | 20.50(4.14) | 0.000* | 18.58(4.09) | 19.33(4.46) | 0.268 | 0.060 | 0.017* |
VO2max | 43.07(18.32) | 50.58(13.88) | 0.027* | 41.35(17.71) | 44.98(16.52) | 0.056 | 0.738 | 0.149 |
Abbreviations: SF-36 the Mos 36-item Short Form Health Survey, PF Physical Functioning, RP Role-Physical, BP Bodily Pain, GH General Health, VT Vitality, SF Social Functioning, RE Role-Emotional, MH Mental Health, HT Reported Health Transition, VO2max maximal oxygen uptake, SPSDCT Stand-up and sit-down chair test (number of times standing up from the chair within 30 s), ALT Arm lifting test (30 s dumb bell of 5 pounds or 2.3Kg lifting test), ANCOV, Analysis of Covariance, ANOVA Analysis of Variance, * p < 0.05